| Primary information |
|---|
| ThPP ID | Th1018 |
| Therapeutic Peptide/Protein Name | Secretin |
| Sequence | HSDGTFTSELSRLRDSARLQRLLQGLV view full sequnce in fasta |
| Functional Classification | IV |
| Molecular Weight | 3056.4 |
| Chemical Formula | C130H219N43O42 |
| Isoelectric Point | 9.45 |
| Hydrophobicity | -0.463 |
| Melting Point (℃) | N.A. |
| Half Life | N.A. |
| Description | This drug is the synthetic form of natural secretin. It is prepared using solid phase peptide synthesis. Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small intestine contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered. |
| Indication/Disease | For diagnosis of pancreatic exocrine dysfunction and gastrinoma |
| Pharmacodynamics | Secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach. |
| Mechanism of Action | Secretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone. |
| Toxicity | N.A. |
| Metabolism | N.A. |
| Absorption | N.A. |
| Volume of Distribution | N.A. |
| Clearance | N.A. |
| Categories | Diagnostic Agents |
| Patents Number | N.A. |
| Date of Issue | N.A. |
| Date of Expiry | N.A. |
| Drug Interaction | Tiotropium.The stimulatory effect of Secretin may be reduced by anticholinergics such as Tiotropium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. |
| Target | N.A. |
| Information of corresponding available drug in the market |
|---|
| Brand Name | N.A. |
| Company | N.A. |
| Brand Discription | N.A. |
| Prescribed for | Testing for stimulation of gastrin secretion to aid in the diagnosis of gastrinoma. |
| Chemical Name | N.A. |
| Formulation | N.A. |
| Physcial Appearnce | N.A. |
| Route of Administration | N.A. |
| Recommended Dosage | N.A. |
| Contraindication | N.A. |
| Side Effects | N.A. |
| Useful Link | http://www.rxlist.com/secreflo-drug.htm |
| PubMed ID | 15780490, 20641871, 25619391 |
| 3-D Structure | Th1018 (View) or (Download) |